Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer. 

Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients. 

Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.

Presenters:

Manali Bhave, MD
Phase I Medical Director
Assistant Professor
Department of Hematology & Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Annalise Labatut, PharmD, BCOP
Oncology Clinical Pharmacy Specialist – Breast Oncology
Emory Healthcare/Winship Cancer Institute
Atlanta, Georgia

Jamie L. Carroll, CNP, APRN, MSN
Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Link to the full program:
https://bit.ly/3UT5Be8

Claim CME Credit:
https://bit.ly/4dBuxhx